HIGHLY ATTENUATED SIV VIF DNA VACCINES

高度减毒 SIV VIF DNA 疫苗

• 批准号: 7349657
• 负责人: Ellen Elizabeth Sparger
• 金额: $ 11.75万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-05-01 至 2007-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7349657
• 关键词: HIGHLY; ATTENUATED; SIV; VIF; DNA

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Objective: Studies in nonhuman primates with simian immunodeficiency virus (SIV) have demonstrated that live-attenuated viruses are highly effective; however, such vaccines maintain a low level of pathogenicity. The objective of this study was to test the immunogenicity of a SIVdeltavif proviral DNA vaccine administered by the IM and ID routes in rhesus macaques and to test for vaccine efficacy by challenge with pathogenic SIVmac251.

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。目的：对感染猴免疫缺陷病毒（SIV）的非人灵长类动物的研究表明，减毒活病毒是高效的；然而，这类疫苗的致病性较低。本研究的目的是测试一种SIVdeltavif前病毒DNA疫苗在恒河猴体内的免疫原性，并通过致病性SIVmac251攻击来测试疫苗的效力。